The patient with serum creatinine 1.5-
Conditions
Interventions
DDAVP 0.3µ
g/kg in NSS 50 ml iv. 30 minutes before kidney biopsy.,NSS 50 ml iv. 30 minutes before kidney biopsy.
Experimental Drug,Placebo Comparator Drug
DDAVP,NSS
Sponsors
Siriraj Institutional Review Board Certificate of Approval
Siriraj Institutional Review Board Certificate of Approval
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >/= 18 years old 2. Native kidney 3. Creatinine >/= 1.5 to < 4 mg/dL 4. BP < 160/80 mmHg before kidney biopsy 5. Normal platelet count and coagulogram
Exclusion criteria
Exclusion criteria: 1. Single kidney 2. Kidney cancer 3. Hydronephrosis or pyelonephritis 4. BMI > 35 kg/m2 5. Dialysis free time < 2 weeks in case indicated dialysis 6. Different kidney size more than 2 cm. 7. The patient who takes antiplatelets or anticoagulants 8. Allergy to DDAVP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Minor bleeding complication: bleeding without blood transfusion nor intervention 6 hours, 24 hours after intervention hemoglobin, hematoma size by ultrasound,Major bleeding complication: bleeding with requirement of blood transfusion or intervention 6 hours, 24 hours after intervention hemoglobin, hematoma size by ultrasound, blood transfusion, angiogram with embolization | — |
Secondary
| Measure | Time frame |
|---|---|
| hematoma size between 2 groups 6 hours ultrasound,the different between vWF Ag, RCO, CBA level between 2 groups 1 hour after DDAVP injection measurement of vWF Ag, RCO, CBA level,the different between platelet aggregation test between 2 groups 1 hour after DDAVP injection platelet aggregation test,side effect of DDAVP 6 hours after DDAVP injection plasma sodium | — |
Contacts
Public ContactRatana Chawanasuntorapoj
Faculty Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed